ラボ自動化市場は、予測期間中に8.15％のCAGRを記録すると予想されます。市場の発展を促進するさまざまな変数があります。最も顕著な市場の推進要因には、研究開発ベンチャーの台頭とラボ自動化フレームワークの受け入れの高まりが含まれます。
バイオテクノロジーおよび製薬企業は、発展する医療のニーズを満たすための研究開発に多大な関心を寄せています。研究開発演習への関心の拡大により、ラボの自動化フレームワークやプログラミングへの関心も高まっています。ラボの自動化は、臨床検査室の作業プロセスの生産性を向上させるのに役立ち、コストの削減とスループットの拡大を通じて投機利益（投資した資金に対する利益）の向上をもたらし、さらに命を救う可能性があります。
さらに、ラボでは、新しい機器やプログラミングなどのイノベーションを継続的に取り入れています。ラボの自動化には、ハードウェアとロボットを機械化するプログラミングの使用が含まれており、人間のわずかな監視の下で動作するため、有効性と結果の性質がさらに向上します。ラボの自動化は、患者がより迅速に優れた治療を受けられるように支援します。
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING INVESTMENT IN R&D ACTIVITIES
4.2.2 RISING ADOPTION OF LABORATORY AUTOMATION SYSTEMS
4.3 RESTRAINTS
4.3.1 HIGH INITIAL CAPITAL INVESTMENTS IN AUTOMATING LABORATORY INFRASTRUCTURE
4.4 OPPORTUNITIES
4.4.1 IMPROVING HEALTHCARE INFRASTRUCTURE ACROSS EMERGING COUNTRIES
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 ENGAGEMENT & DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES FOLLOW-UPS
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF BUYERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE LABORATORY AUTOMATION MARKET
5.3.1 OVERVIEW
5.3.2 IMPACT ON COST OF RAW MATERIALS
5.3.3 IMPACT ON AVAILABILITY OF PRODUCTS
5.3.4 IMPACT ON TRADE (IMPORT/EXPORT)
6 GLOBAL LABORATORY AUTOMATION MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 AUTOMATED WORKSTATIONS
6.2.1 AUTOMATED LIQUID HANDLING
6.2.1.1 AUTOMATED INTEGRATED WORKSTATIONS
6.2.1.2 PIPETTING SYSTEMS
6.2.1.3 REAGENT DISPENSERS
6.2.1.4 MICROPLATE WASHERS
6.2.2 MICROPLATE READERS
6.2.2.1 MULTI-MODE MICROPLATE READERS
6.2.2.2 SINGLE-MODE MICROPLATE READERS
6.2.3 AUTOMATED ELISA SYSTEMS
6.2.4 AUTOMATED NUCLEIC ACID PURIFICATION SYSTEMS
6.3 ROBOTIC SYSTEMS
6.4 SOFTWARE & INFORMATICS
6.4.1 ELECTRONIC LABORATORY NOTEBOOK
6.4.2 WORKSTATION/UNIT AUTOMATION SOFTWARE
6.4.3 SCIENTIFIC DATA MANAGEMENT SYSTEM
6.4.4 LABORATORY INFORMATION MANAGEMENT SYSTEM
6.5 OTHERS
7 GLOBAL LABORATORY AUTOMATION MARKET, BY PROCESS
7.1 OVERVIEW
7.2 CONTINUOUS FLOW
7.2.1 WORKFLOW
7.2.1.1 SEQUENTIAL PROCESSING
7.2.1.2 PARALLEL PROCESSING
7.2.2 COMPONENTS
7.2.2.1 CONSUMABLES
7.2.2.2 EQUIPMENT
7.3 DISCRETE PROCESSING
7.3.1 METHOD
7.3.1.1 CENTRIFUGAL DISCRETE PROCESSING
7.3.1.2 RANDOM ACCESS DISCRETE PROCESSING
7.3.2 COMPONENTS
7.3.2.1 CONSUMABLES
7.3.2.2 EQUIPMENT
7.3.3 WORKFLOW
7.3.3.1 DEPENDENT ANALYSIS
7.3.3.2 INDEPENDENT ANALYSIS
8 GLOBAL LABORATORY AUTOMATION MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 CLINICAL DIAGNOSTICS
8.3 GENOMICS SOLUTIONS
8.4 PROTEOMICS SOLUTIONS
8.5 DRUG DISCOVERY
8.6 OTHERS
9 GLOBAL LABORATORY AUTOMATION MARKET, BY END USER
9.1 OVERVIEW
9.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
9.3 HOSPITALS & DIAGNOSTIC LABORATORIES
9.4 RESEARCH & ACADEMIC INSTITUTES
10 GLOBAL LABORATORY AUTOMATION MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.2.3 MEXICO
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UK
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 NETHERLANDS
10.3.7 SWEDEN
10.3.8 RUSSIA
10.3.9 POLAND
10.3.10 AUSTRIA
10.3.11 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 TAIWAN
10.4.7 SINGAPORE
10.4.8 MALAYSIA
10.4.9 THAILAND
10.4.10 REST OF ASIA-PACIFIC
10.5 LAMEA
10.5.1 SOUTH AFRICA
10.5.2 SAUDI ARABIA
10.5.3 UNITED ARAB EMIRATES
10.5.4 EGYPT
10.5.5 REST OF LAMEA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL LABORATORY AUTOMATION MARKET
11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL LABORATORY AUTOMATION MARKET
11.5 KEY DEVELOPMENT ANALYSIS
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
11.6.2 PARTERSHIP/AGREEMENT
11.6.3 MERGER /ACQUISTION
11.7 FINANCIAL MATRIX
11.7.1 SALES (USD MILLION), 2021
11.7.2 R&D EXPENDITURE (USD MILLION), 2021
12 COMPANY PROFILES
12.1 THERMO FISHER SCIENTIFIC INC.
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL ANALYSIS
12.1.3 PRODUCTS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 AGILENT TECHNOLOGIES INC.
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 TECAN TRADING AG
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIES
12.4 BIOMÉRIEUX SA
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGIES
12.5 SIEMENS HEALTHINEER
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 BECKMAN COULTER, INC.
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIES
12.7 QIAGEN N.V.
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 PERKINELMER INC.
12.8.1 COMPANY OVERVIEWS
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIES
12.9 HAMILTON COMPANY
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 F. HOFFMANN-LA ROCHE LTD
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 SWOT ANALYSIS
12.10.6 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS
